NYSE: $LLY Understanding the FDA Approval The FDA has officially expanded the approval of Olumiant (baricitinib) to include pediatric patients aged 12 years and older who suffer from severe alopecia areata. This milestone marks a significant step forward, as it provides a new, targeted treatment option for adolescents navigating the emotional and physical challenges of…